RP-3 is under clinical development by Replimune and currently in Phase I for Melanoma. According to GlobalData, Phase I drugs for Melanoma have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how RP-3’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RP-3 is under development for the treatment of advanced solid tumors including head and neck cancer, lung cancer, breast cancer, gastric cancer, head and neck cancer squamous cell carcinoma, metastatic hepatocellular carcinoma, micro-satellite stable colorectal cancer (CRC), melanoma and liver metastases, soft tissue sarcomas including leiomyosarcoma, osteosarcoma, chondrosarcoma, myxofibrosarcoma and epithelioid sarcomas. RP3 is a genetically modified herpes simplex type 1 virus (HSV-1) that expresses exogenous genes (anti-CTLA-4 antibody, 4-1BB ligand and CD40 ligand). It is administered by intratumor route. The drug candidate is an oncolytic immunotherapy and is developed based on Immulytic platform.
Replimune, a subsidiary of Replimune Group Inc, is a pharmaceutical company that develops oncolytic immunotherapies for the treatment of cancer. The company’s pipeline products include RP1 used for the treatment of oncolytic immunotherapy backbone, and RP2 and RP3 for expressing anti-CTLA-4 and co-stimulatory ligands. Its Immulytic platform is designed to maximize systemic immune activation in tumor neoantigens, through viral-mediated immunogenic tumor cell killing and deliver optimal combinations of immune-activating proteins into a tumor and draining lymph nodes. Replimune is headquartered in Abingdon, Oxfordshire, the UK.
For a complete picture of RP-3’s drug-specific PTSR and LoA scores, buy the report here.